Charles Rivera: Unscripted
Insightful analysis on the progress, people, and partnerships defining modern service.
About This Column
Description: Charles Rivera is a commentator and strategist dedicated to the intersection of community support and institutional innovation. Building on a career spent celebrating the successes of veterans and first responder programs, Charles now delivers daily dispatches on the broad forces shaping our shared wellbeing. With a reputation for providing a nuanced perspective on "the why" behind effective service, he offers a unique lens on how organizations can amplify their positive impact through dedicated investment and innovative thinking. His writing is essential for anyone seeking a more connected and equitable future.
Displaying items 161-180 of 799 in total
Intel and Ultralytics: Rewiring the Edge to Bring AI Everywhere
Karman's PA Expansion: A Local Investment for National Maritime Strength
Illuminating Independence: A Simple Innovation Redefines Home Safety
SOGOAPP's Gambit: Can Privacy and Profit Coexist in Social Media?
Beyond the Award: The Unseen Partnerships Fortifying National Defense
Ategrity's Blueprint: How Innovation Forges Record Insurance Profits
CoreWeave's Gartner Nod Signals a New Era for Specialized AI Clouds
InMode Under Siege: A Shareholder Revolt Exposes Deep Governance Cracks
A Bet on Independence: Why Matthews International's Founders Bought Back Their Firm
Valid8's FedRAMP Push: A New Era for Government Financial Forensics
The Next Niobec? A Calculated Bet on Québec's Critical Minerals Future
Beyond the Cloud: How GIGABYTE is Powering On-Premise AI Breakthroughs
Helius Stands Firm on Serra Pelada Amidst a Revived Legal Ghost
Capital with a Conscience? A $170M Bet on Pediatric Dental Care
Aris Mining: Strong Results Fuel an Ambitious South American Vision
Beyond the Soundbites: A New Contender Redefines Service in FL-27
The Digital Host: Can AI Bring the Human Touch Back to the Casino Floor?
Service and Strategy: A Veteran’s Pivot to Austin’s Wellness Boom
The $1.5B Bet: How a UK Biotech Is Reshaping Big Pharma's Cancer Fight
